ERBB2 and neoplasm: For example, both detargeting and retargeting have been achieved in VSVs engineered to engage tumor-restricted receptors (e.g., HER2-directed chimeric glycoproteins or adapter systems), which enhanced tumor tropism and reduced off-tumor infection [24].